ApoCell is a very active member of the biopharma research community and routinely attends many key events and conferences a year. We often present our recent work in collaboration with our clients in poster & podium presentations so be sure to keep an eye out and check us out at the next event!

Conference

  • Jan 1 - Jan 1, 2011
  • Past Conferences

Wu W, A et. Al., “High Content Imaging and Characterization of Circulating Tumor Cells (CTC) from Cancer Patients.”

Conference

  • Nov 1 - Nov 1, 2010
  • Past Conferences

Davis, DW et. Al.,“Molecular Characterization of Circulating Tumor Cells Using a Highly Sensitive Method of Enrichment Based on the CellSearch…

Conference

  • Oct 1 - Oct 1, 2010
  • Past Conferences

Abstract #1335P, Eisen, A et. Al., “CTC Biomarker Assessment To Aid Dosing Selection of E6201, A Potent MEK1 Inhibitor, For…

Conference

  • Jun 1 - Jun 1, 2010
  • Past Conferences

Abstract #3093, Davis, DW et. Al., “Sensitive Detection of Gamma-H2AX Induction as a Pharmacodynamic Marker for Profiling Patients With Cancer…

Conference

  • Apr 1 - Apr 1, 2010
  • Past Conferences

Abstract # 2687, Melnikova VO et. Al., “Development of a New, Highly Sensitive Assay for Circulating Tumor Cell (CTC) Detection…

Conference

  • Nov 1 - Nov 1, 2009

Davis, DW et. Al., “Prospective Real-time Analysis of P-cadherin Expression to Select Patients into a Phase I Oncology Trial” Abstract…

Conference

  • Nov 1 - Nov 1, 2009
  • Past Conferences

Davis, DW et. Al., “Prospective Real-time Analysis of P-cadherin Expression to Select Patients into a Phase I Oncology Trial” Abstract…

Conference

  • May 1 - May 1, 2009
  • Past Conferences

Abstract #3525, Davis, DW et. Al., “Circulating Tumor and Endothelial Cells as Pharmacodynamic Biomarkers in a Phase I Clinical Trial…

Conference

  • May 1 - May 1, 2007
  • Past Conferences

Abstract #8021, Davis, DW, et. al., “pKDR/KDR Ratio as Possible Predictor of Response in Phase I/II Study of Erlotinib and…

Conference

  • Jan 1 - Jan 1, 2007
  • Past Conferences

Abstract #C165, Davis, DW et. al.,”Predictive Markers of Response in a Phase I/II Pharmacodynamic (PD) Study of Erlotinib and Bevacizumab…